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Background. RTS,S/AS01E is the lead candidate malaria vaccine and confers pre-erythrocytic immunity.
Vaccination may therefore impact acquired immunity to blood-stage malaria parasites after natural infection.
Methods. We measured, by enzyme-linked immunosorbent assay, antibodies to 4 Plasmodium falciparum
merozoite antigens (AMA-1, MSP-142, EBA-175, and MSP-3) and by growth inhibitory activity (GIA) using 2
parasite clones (FV0 and 3D7) at 4 times on 860 children who were randomized to receive with RTS,S/AS01E or
a control vaccine.
Results. Antibody concentrations to AMA-1, EBA-175, and MSP-142 decreased with age during the first year of
life, then increased to 32 months of age. Anti–MSP-3 antibody concentrations gradually increased, and GIA
gradually decreased up to 32 months. Vaccination with RTS,S/AS01E resulted in modest reductions in AMA-1, EBA-
175, MSP-142, and MSP-3 antibody concentrations and no significant change in GIA. Increasing anti-merozoite
antibody concentrations and GIA were prospectively associated with increased risk of clinical malaria.
Conclusions. Vaccination with RTS,S/AS01E reduces exposure to blood-stage parasites and, thus, reduces anti-
merozoite antigen antibody concentrations. However, in this study, these antibodies were not correlates of clinical
immunity to malaria. Instead, heterogeneous exposure led to confounded, positive associations between increasing
antibody concentration and increasing risk of clinical malaria.
Malaria remains a global health problem [1], despite the
recent increase in insecticide-treated bed-net (ITN)
provision and highly effective artemisinin combination
therapy [2–4]. A malaria vaccine is needed for sustained
control.
RTS,S is a candidate malaria vaccine based on the
circumspozoite protein (CSP) that targets the pre-
erythrocytic cycle of Plasmodium falciparum in humans
[5]. Vaccination with RTS,S has been partially effica-
cious against clinical malaria in the field when given
with either the AS01 or AS02 adjuvant system [6, 7].
RTS,S-containing vaccines induce pre-erythrocytic im-
munity [8], differing from naturally acquired immunity,
which largely targets blood-stage parasites [9].
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The protection conferred by RTS,S against a given sporozoite
inoculum may be partial, resulting in a reduced number of
merozoites being released into the bloodstream [10]. This de-
crease in initial merozoite inoculum may result in a quantita-
tively and/or qualitatively superior blood-stage immune
response [11]. An alternative hypothesis is that reduced expo-
sure to blood-stage parasites will result in reduced immunity to
malaria in the long term, as described in some studies of ITN use
[12].
The mediators of natural immunity to malaria are
incompletely understood [9]. Nevertheless, it is known that
antibodies to merozoite antigens inhibit parasite invasion of
erythrocytes in vitro [13] and that their presence correlates with
resistance to development of clinical malaria in prospective
immuno-epidemiological studies [14].
In this study, we aimed to determine whether antibody
responses to merozoite antigens are higher or lower in chil-
dren receiving RTS,S vaccination, compared with control
vaccinees. We therefore analyzed plasma and serum samples
collected during a phase IIb randomized, controlled trial of
RTS,S/AS01E among young children in Kilifi, Kenya, and
Korogwe, Tanzania [7]. We assayed antibodies to 4 different
merozoite antigens with use of enzyme-linked immunosor-
bent assay (ELISA) and assayed the growth inhibitory activity
(GIA) in serum samples against in vitro parasite cultures. We
analyzed the effect of vaccination on the acquisition of these
serological responses and looked for correlations between
these antibody responses and protection from clinical malaria
episodes.
METHODS
Study Design
In Kilifi, Kenya, and Korogwe, Tanzania, 894 children aged 5–
17 months were randomized in a 1:1 ratio to receive 3 doses at
monthly intervals of either RTS,S/AS01E or rabies vaccine, to
evaluate the efficacy and safety of RTS,S/AS01E against clinical
malaria episodes by P. falciparum infection. Details have been
published elsewhere [7]. The study protocol and its sub-
sequent amendments received ethical and scientific approval
from the Kenyan Medical Research Institute National Ethics
Committee, the Tanzanian Medical Research Coordinating
Committee, the Tanzania Food and Drug Authority, the
Oxford Tropical Research Ethics Committee, the London
School of Hygiene and Tropical Medicine Ethics Committee,
and the Western Institutional Review Board in Seattle. The
study was overseen by an independent data-monitoring
committee and local safety monitors and was conducted in
accordance with the Helsinki Declaration of 1964 (revised
1996) and Good Clinical Practice guidelines. Written in-
formed consent in the local languages (Swahili or Giriama)
was required for participation.
Monitoring for Episodes of Clinical Malaria
The primary end point was a clinical episode of malaria, defined
as an axillary temperature R37.5C, with a P. falciparum load
.2500 parasites/lL. Active surveillance was implemented with
weekly home visits by fieldworkers to identify febrile chil-
dren. Passive surveillance was implemented by fieldworkers
residing in the study villages and health care staff in local
health facilities.
Blood Samples
Blood samples were taken (1) before vaccination, (2) 1 month
after dose 3, (3) in March 2008 (ie, mean, 8 months; range, 4–10
months after dose 3), and (4) 12 months after dose 3. Blood
samples were collected in serum separator tubes for the growth-
inhibitory assay studies and into lithium heparin tubes for
ELISA studies. Separated serum and plasma was aliquoted and
stored at 280oC until assayed.
ELISA
Samples were tested by ELISA for the presence of human IgG
against the following P. falciparum antigens as described else-
where [15]: MSP-142, 3D7 sequence expressed in Escherichia coli
[16]; MSP-3, FVO sequence, expressed in E. coli [17]; the
receptor-binding domain II (PfEBA-175RII) of EBA-175, 3D7
sequence, expressed in P. pastoris [18]; and AMA-1, 3D7
sequence expressed in E. coli [19]. In brief, each antigen was
coated onto high absorbance plates (Immulon4 HBX) at a con-
centration of 0.5 lg/mL and stored at 4C overnight. The plates
were washed 3 times in phosphate-buffered saline (PBS) with
0.05% Tween 20 (PBS-T) and blocked for 3 h with blocking
buffer (1% w/v dried skimmed milk powder in PBS-T). After 3
additional washes, 100 lL of each plasma sample were added to
duplicate wells at a final dilution of 1/1000 in PBS-T. The next
day, after 5 washes, 100 lL of horse radish peroxidase–conjugated
antihuman IgG (DAKO) at a dilution of 1:5000 in blocking buffer
was added to each well, and plates were incubated for 3 h. The
plates were then developed using H202 as substrate and OPD
(Sigma) as the colorimetric indicator for 20 min in the dark.
Plates were read at 492 nm on a Molecular Devices Versa Max
ELISA reader. Tests were repeated if duplicate optical density
(OD) values for an individual plasma sample varied by more than
a factor of 1.5. OD readings were normalized against the 1:600
positive control dilution. A pool of serum samples from an area
in Africa where malaria is highly endemic was titrated on each
plate as a positive control. A 3-parameter sigmoid ligand binding
model was used to least-squares fit a curve to the values of the
hyperendemic serum sample pool, and this was used to calculate
sample antibody concentrations on each plate.
Growth-Inhibitory Assay
Growth-inhibitory assays were performed at the Walter Reed
Army Institute of Research according to previously published
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methods [20, 21]. Serum samples (50 lL total volume)
were dialyzed using 20K MWCO Slide-A-Lyzer Mini-Dialysis
Units (Pierce) with 3 buffer exchanges against 1x PBS and a
final exchange against RPMI (Invitrogen). Plasma samples were
preabsorbed with human red blood cells (RBCs; blood group O)
and tested for GIA by measuring the inhibition of parasite lac-
tate dehydrogenase activity. Parasitized RBC cultures of both the
3D7 and the FVO parasite lines at the early schizont stage were
established in cultures with 0.3% parasitemia and 2% he-
matocrit in culture medium containing 10% test plasma.
Assay plates were sealed in bags containing 5% carbon di-
oxide, 5% oxygen, and 90% nitrogen and were incubated for
40 or 48 h (cycle time of 3D7 and FVO parasites, respectively).
Cultures were then harvested by adding 80 lL/well PBS and
spinning plates for 10 min at 10,000 g. Plates were then frozen
at 230 C until analysis. To quantify parasite lactate de-
hydrogenase activity, a substrate buffer containing 0.1 M Tris
HCl (pH, 8.0), 50 mM sodium-L-lactate, 0.25% Triton-X, 10
mg NBT, 10 lg/mL 3-Acetylpyridine, and 10 U/mL di-
aphorase from Clostridium klyiveri (Sigma) was added to each
well. Colorimetric measurement at 650 nm was done after 30
min of reaction time with use of a SpectraMax Plus 384
spectrophotometer (Molecular Devices). Calculation of GIA
was determined by using the formula: percentage inhibition5
[1-[(OD immune plasma—OD RBC)/(OD malaria naive
plasma—OD RBC)]] 3 100.
Statistical Analysis
Antibody scores from ELISAs were log-transformed to
normalize distributions before analysis. Growth-inhibitory
assay results were normally distributed and analyzed without
prior transformation. We did not restrict fitting age and
calendar date to linear effects. For instance, it is possible that,
at young ages, antibody is acquired less rapidly (or even lost as
maternal antibody decays). We therefore allowed for
nonlinear effects by selecting multivariable fractional
polynomials with use of the Royston and Altman algorithm
from Stata, version 10 (StataCorp), entering age and calendar
date simultaneously in the model. This allows the model to
optimize the model fit using power and log functions to
approximate the shape of the relationship between age and
date and antibody [22]. Analyses were adjusted for fixed
effects of location and bed-net use. The effect of vaccination
was examined, adjusting for both the fractional polynomial fit
for age and date and the antibody concentrations for each
individual that was measured before vaccination. The effect of
vaccination on log-transformed data was presented as a pro-
portional difference (ie, 10 coefficient). Cox regression was
used for survival analysis when the effect of antibody from all
4 times was related to clinical malaria episodes during the
period of monitoring after each measurement. Therefore, each
participant could contribute to 4 periods of monitoring, and
the sandwich estimator was used to cluster analysis by
individual [23]. Regression was also adjusted by fixed effects for
age, village, distance from the health facility, and bed-net use.
Determination of Malaria Transmission Zones
SaTScan software [24] was used to calculate the spatial scan
statistic [25]. The spatial scan statistic uses a scanning win-
dow that is moved across space throughout the study area.
For each location and size of the window, the number of
expected cases of clinical malaria is calculated, based on the
expectation of an even distribution across the population.
The ratio of observed to expected cases is counted, and the
window with the greatest ratio of observed to expected cases
is noted. We set the scan window to a maximum size of 30%
of the population, where P , .05 and the observed to
expected ratio was .2.
Distinguishing Exposure and Immunity
A logistic model was used to compare the risk of clinical
malaria among all children who were definitely exposed to
malaria infection. Children were therefore assigned 2 cate-
gories: cases of clinical malaria (ie,R1 episode of an axillary
temperature .37.5C, with a P. falciparum load .2500
parasites/lL) or controls (ie, asymptomatic P. falciparum
parasitemia on either of the 2 cross-sectional surveys).
RESULTS
In total, 2915 plasma samples collected at 4 times (at screening
and 1, 8, and 12 months after the third vaccination) from 866
children were tested for antibody concentrations. In addition,
2417 serum samples collected at 3 different times (at screening
and 8 and 12 months after the third vaccination) were tested
for growth inhibiting activity with use of 2 different parasite
clones.
Age and Calendar Date
The best-fit fractional polynomials for the age profile of
antibody concentrations suggested that, for AMA-1, EBA-
175, and MSP-142, antibody concentrations were highest in
the youngest children tested, decreased to a nadir just before
1 year of age, and then steadily increased in older children
(Table 1, Figure 1a). The best fit for anti–MSP-3 antibody
concentrations suggested a simple linear increase in con-
centrations with increasing age (Table 1). GIA steadily
decreased with increasing age (Table 1).
Significant variation in antibody concentrations over time
was seen for all antigens (after adjusting for age), with an
initial increase, then decrease, such that the final concen-
trations (November 2008) were lower than the baseline con-
centrations (January 2007). This was not entirely synchronous
with changes in malaria transmission, because antibody
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concentrations continued to decrease steadily throughout the
period when the highest levels of transmission were observed
during April–June 2008 (Figure 1d). GIA decreased steadily
throughout the study period (Table 1, Figure 1c).
Vaccination and Antibody Concentration
Vaccination with RTS,S/AS01E was associated with statistically
significant decreases in antibody concentration, with pro-
portional differences of 0.85–0.73 for the 4 merozoite antigens
tested (ie, reductions in antibody concentration were 15%–27%)
(Table 2). However, the occurrence of R1 episodes of clinical
malaria in the 3 months before measuring antibody concen-
trations had a more marked effect on antibody concentrations,
with proportional differences of 2.48–10.55 (ie, antibody con-
centrations were 2.5- to 10-fold higher among children who had
recently experienced a clinical malaria episode than among those
who had not). Furthermore, adjusting the effect of vaccination
for prior episodes of clinical malaria reduced both the effect size
and statistical significance of the effect of vaccination (Table 2).
Growth-inhibitory assay results were not influenced by vacci-
nation but were higher after episodes of malaria.
Antibody Concentration and Subsequent Risk of Clinical Malaria
For Cox regression models, the unit of analysis was the period of
observation after each antibody measurement. Therefore, each of
the 866 participants could contribute up to 3 periods (after
baseline and 1 and 6 months after the third vaccination). Among
these time periods, there were 277 first or only episodes of clinical
malaria (ie, axillary temperature R37.5oC and parasite load
R2500 parasites/lL) during 9580 months of monitoring. After
adjusting for vaccination group, there were positive associations
between increasing antibody concentration and an increased
subsequent risk of clinical malaria for anti–AMA-1, MSP142, and
EBA-175 antibody concentrations and for GIA (Table 3). Sur-
vival plots by antibody quartile are shown in Figure 2.
Further analysis did not provide any evidence that the sub-
group of children with antibody concentrations above the me-
dian at 3 separate clinic visits (ie, over a period of 6–12 months)
had lower risk of clinical malaria than did children with unstable
antibody concentrations (Table 4).
Intensity of Malaria Transmission and Antibody Concentrations
To test the hypothesis that exposure to malaria infection
confounds the analysis by leading to both higher antibody
concentrations and ongoing higher risk of future malaria in-
fection, we identified the geographical area with highest in-
cidence of clinical malaria cases among the cohort with use of
SaTScan. Antibody concentrations were higher in the high-
transmission area (Figure 3). Antibody concentration pre-
dicted residence in the high-transmission area for AMA-1
(odds ratio [OR], 1.17; 95% confidence interval [CI], 1.06–
1.29; P 5 .002), EBA-175 (OR, 1.13; 95% CI, 1.03–1.26;
P5 .015), MSP-142 (OR, 1.22; 95% CI, 1.12–1.34; P, .0005),
MSP-3 (OR, 1.22; 95% CI, 1.09–1.36; P,.0005), GIA for 3D7
Table 1. Predicted Antibody Concentrations/GIA With Age and Calendar Date, Using Results From All Four Cross-Sectional Studies
Transformation (power) P
Predicted concentration according to model.
Peak/trough Youngest age/earliest timepoint Oldest age/latest timepoint
AMA-1
Date y 5 m1*x
22 1 m2*x
22*ln(x) ,.0001 29.4 6.0 4.2
Age y 5 m1*x
20.5 1 m2*ln(x) ,.0001 26.0 965.4 76.6
MSP-3
Date y 5 m1*x
22 1 m2*x
22*ln(x) ,.0001 37.7 26.6 11.8
Age m1*x .005 23.9 56.2
EBA-175
Date y 5 m1*x
22 1 m2*x
22*ln(x) ,.0001 49.5 15.0 12.1
Age y 5 m1*x
22 1 m2*x
22*ln(x) ,.0001 29.2 473.5 63.3
MSP-142
Date y 5 m1*x
21 1 m1*x
0.5 ,.0001 26.5 14.7 8.3
Age y 5 m1*x
22 1 m2*x
22*ln(x) ,.0001 14.0 145.2 69.0
GIA for 3d7
Date m1*x ,.0001 NA 29.8 16.3
Age m1*x .13 NA 20.8 25.1
GIA for FV0
Date y 5 m1*x
22 1 m2*x
22*ln(x) .003 NA 65.8 51.9
Age m1*x .065 NA 63.8 59.8
NOTE. The transformation returned by multivariable fractional polynomial is shown in the first column (x refers to antibody levels and m refers to the coefficients
fit by the model). Where a linear association is reported, the P value given is the conventional significance of line with a gradient linear trend compared with no
gradient. Where a nonlinear transformation is reported, the P value refers to the significance of the nonlinear transformation compared with a linear trend.
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(OR, 1.13; 95% CI, 1.10–1.18; P , .0005), and GIA for FV0
(OR, 1.30; 95% CI, 1.24–1.37; P , .0005).
Distinguishing Exposure and Immunity
To reduce the confounding from variable exposure to malaria
infection, we conducted a subgroup analysis of only those
children who were definitely exposed to malaria infection
(ie, children who had either asymptomatic parasitemia or an
episode of clinical malaria) [26]. This effectively excludes the
children who had no episode of clinical malaria as a result of not
being exposed to infectious bites rather than as a result of being
immune [27] (although the exposure could, theoretically, have
Figure 1. A, Scatter plot of age (x axis) against AMA-1 antibody concentration with the fitted fractional polynomial: Concentration5m1*age
20.5 1
m2*ln(age), where m refers to coefficients fitted by the regression model. B, Scatter plot of calendar date (x axis) against AMA-1 antibody concentration
with the fitted fractional polynomial: Concentration5m1*date
221 m2*date
22 *ln(date). C, Scatter plot of calendar date (x axis) against GIA for FV0 parasites
with the fitted fractional polynomial: Concentration5m1*date
22 1 m2*date
22 *ln(date). D, The incidence of clinical malaria per month by calendar month.
Table 2. Effect of Vaccination on Antibody Concentrations/GIA
RTS,S/AS01E compared with
control, unadjusted Previous episodes
RTS,S/AS01E compared with
control, adjusted for episodes
Prop dif P Prop dif P Prop dif P
AMA-1 0.83 (0.7–.97) .021 4.8 (3.65–6.31) ,.0001 0.88 (.75–1.03) .1
EBA-176 0.85 (.73–.99) .039 2.48 (2.03–3.05) ,.0001 0.88 (.76–1.03) .108
MSP-142 0.73 (.59–.9) .004 10.55 (7.41–15.02) ,.0001 0.8 (.65–.97) .026
MSP3 0.81 (.68–.96) .017 2.26 (1.72–2.95) ,.0001 0.84 (.71–1) .051
GIA, 3D7 parasites 2.41% (21.9 to 11.1%) .591 17.0% (3.6–10%) ,.0001 1.02% (21.5 to 11.5%) .98
GIA, FV0 parasites 2.8% (22 to 1.5%) .216 15.7% (3.4–8%) ,.0001 2.6% (21.8 to 1.7%) .35
NOTE. Effect sizes are shown as proportional differences for log transformed antibody concentrations (ie, 2.03 5 2.03-fold increase) and absolute difference
for % growth inhibitory activity.
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occurred before vaccination). The analysis compared the 52
children who had asymptomatic parasitemia at either the sixth
or seventh clinic visits (control participants) with the 171 chil-
dren who had at least 1 episode of clinical malaria during the 3
months before these clinic visits (case participants).
The ORs for clinical malaria versus asymptomatic infection
associated with increasing log-transformed antibody concen-
trations were not significantly different from unity: AMA-1 (OR,
.87; 95% CI, 0.6–1.4; P 5 .6), MSP-142 (OR, .97; 95% CI, 0.7–
1.4; P5 .8), MSP-3 (OR, .87; 95% CI, 0.5–1.4; P5 .6), EBA-175
(OR, .99; 95% CI, 0.5–1.8; P 5 .9), GIA for 3D7 (OR, 1.1; 95%
CI, 0.9–1.4; P 5 .2), or GIA for FV0 (OR, 1.2; 95% CI, 0.9–1.6;
P5 .17). To take AMA-1 as an example, each 10-fold increase in
antibody concentration was associated with a 13% reduction in
the risk of clinical malaria as opposed to asymptomatic malaria
(95% CI, –40% to 40%).
However, ITN use (OR, 2.38; 95% CI, 1.2–4.8; P5 .014) and
vaccination with RTS,S/AS01E (OR, 2.36; 95% CI, 1.1–5.0;
Figure 2. Kaplan Meier plots showing proportions of children without clinical malaria episodes according to quartile of antibody or GIA responses
measured directly prior to periods of follow-up (ie, there are up to 3 observations for each individual: malaria incidence in the 2.5 months after antibody
assessments at enrollment and at months 8 and 12 after the third vaccination).
Table 3. Cox Regression Model for Risk of Clinical Malaria Episodes (TempR37.5C andR2500 Parasites/mL) by Blood Stage Antigens
Antigen
All subjects RTS,S/AS01E vaccinees Control vaccinees
HR (95%CI) P HR (95%CI) P HR (95%CI) P
AMA-1 1.91 (1.54–2.36) ,.0001 2.40 (1.74–3.30) ,.0001 1.68 (1.27–2.22) ,.0001
EBA-175 1.39 (1.05–1.84) .02 1.68 (.976–2.92) .06 1.24 (.902–1.72) .18
MSP-142 1.67 (1.40–2.00) ,.0001 2.16 (1.59–2.94) ,.0001 1.48 (1.19–1.83) ,.0001
MSP-3 1.29 (1.00–1.65) .042093 1.56 (.936–2.62) .09 1.16 (.886–1.54) .27
GIA for 3D7 1.15 (1.07–1.23) ,.0001 1.16 (1.05–1.29) .003 1.14 (1.03–1.27) .008
GIA for FV0 1.24 (1.09–1.40) ,.0001 1.20 (1.00–1.43) .04 1.27 (1.07–1.50) .005
NOTE. Hazard ratios (HR) and 95% confidence intervals (95%CI) are shown for each log-fold increase in antibody level. HRs are adjusted for vaccination group for
the all-subjects analysis, and for village, bednet use, distance from the dispensary, period of monitoring, and age for all analyses. Age was not a significant factor
(HR 5 1.01, 95%CI .98–1.05).
14 d JID 2011:204 (1 July) d Bejon et al
P 5 .023) were significantly associated with increased odds of
clinical malaria, compared with asymptomatic infection.
Although both ITN use and vaccination reduce the risk of
clinical malaria [7, 28], these interventions have an even bigger
effect on reducing the risk of asymptomatic infection.
DISCUSSION
We compared antibody responses to P. falciparum asexual
blood-stage antigens between individuals vaccinated with the
malaria vaccine RTS,S/AS01E and those receiving a control
vaccine. Anti-merozoite antigen antibody concentrations were
lower among RTS,S/AS01E–vaccinated children than among
control children after adjusting for age, calendar date, and
previous antibody concentration. However, the magnitude of
this effect was modest in a cohort with a clinical malaria in-
cidence of 0.53 episodes per child per year. For example, AMA-1
antibody concentrations varied by .10-fold over the age range
of 5–32 months, but vaccination with RTS,S/AS01E was
associated with only a 17% reduction in AMA-1 antibody
concentrations. After adjusting for previous episodes of malaria,
the effect of vaccination was less apparent and no longer sig-
nificant, suggesting that vaccination reduces antibody levels by
reducing exposure to malaria. However, previous malaria
episodes could not explain all the effect of vaccination, possibly
because some exposures to malaria parasites are not detected as
clinical malaria cases.
Antibody concentrations initially decreased in very young
children, presumably reflecting metabolic decay of maternally
derived antibodies, but subsequently increased with increasing
age, presumably reflecting endogenous production after malaria
infection. GIA decreased with increasing age, as has been re-
ported in previous studies [29, 30].
Among P. falciparum–infected individuals, ITN use and
vaccination with RTS,S/AS01E were associated with increased
risk of clinical malaria, compared with asymptomatic para-
sitemia. This suggests that the reduced risk of clinical malaria
conferred by RTS,S/AS01E in this cohort [7] is partially offset
by a shift from asymptomatic infection to clinical malaria. A
similar shift in outcome has been described previously for
ITN use [12]. RTS,S/AS01E or ITN use protects against
clinical malaria and against asymptomatic infection but is
somewhat more protective against asymptomatic infection
than against clinical malaria. This may reflect reduced or
delayed acquisition of blood-stage immunity, so that the
blood-stage infections that occur in vaccinated (or ITN-us-
ing) children are more likely to progress to clinical disease.
Taken together with the lower concentrations of antibodies
to merozoite antigens among RTS,S/AS01E vaccinees, we
conclude that the long-term protective efficacy of RTS,S
vaccination is more likely to be a direct effect of the pre-
erythrocytic immunity induced by the vaccine [31], rather
than the result of enhanced acquisition of immunity to
blood-stage antigens [32].
We did not clear asymptomatic parasitemia before follow-up;
thus, the exposure inferred from asymptomatic parasitemia on
subsequent blood samples may have occured before vaccination.
However, the surveys for asymptomatic parasitemia were con-
ducted at a mean of 8 and 12 months after vaccination, and
relatively few infections persist for this long [33]. Furthermore,
because vaccination group was randomly allocated, the differ-
ences in prevalence of asymptomatic parasitemia by vaccination
group are likely to reflect postvaccination exposure.
Anti-merozoite antibodies and GIA were associated with
highly significant increases in the prospective risk of clinical
malaria. We conclude that this association was confounded by
exposure to malaria infection, because (1) malaria transmission
was heterogeneous in our study area, as in many other cohorts
[34–37]; (2) antibody concentrations were highest in the area of
highest transmission; and (3) when we analyzed the risk of
clinical malaria versus asymptomatic infection (ie, excluding the
uninfected children who may have been unexposed rather than
immune), antibody concentrations were no longer associated
with either immunity or susceptibility to clinical malaria. Ma-
laria exposure leads to higher antimalarial antibody levels and
a higher risk of clinical malaria.
Table 4. Cox Regression Model for Risk of Clinical Malaria
Episodes (Temp R37.5C and R2500 Parasites/mL) by Blood
Stage Antigens, Classified Into Stable Low Titres, Stable High
Titres, or Unstable Titres
N
Hazard
ratio
Lower
CI
Upper
CI P
AMA-1
Unstable 306 1
Stable high 81 1.13 .66 1.95 .66
Stable low 65 0.40 .16 .99 .05
EBA-175
Unstable 308 1
Stable high 92 0.75 .43 1.31 .32
Stable low 61 0.54 .26 1.14 .11
MSP-142
Unstable 276 1
Stable high 88 1.57 .91 2.69 .11
Stable low 96 0.80 .39 1.64 .54
MSP-3
Unstable 308 1
Stable high 78 1.28 .69 2.38 .44
Stable low 86 1.02 .59 1.75 .94
NOTE. GIA data were not available for the 2nd clinic visit, and so could not
be included. Concentrations are classified as stable and high if they are above
the median for the first 3 clinic visits, and stable and low if they are below the
median for the first 3 clinic visits. HRs are adjusted for vaccination group,
village, bednet use, distance from the dispensary, period of monitoring, and age
for all analyses.
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However, an alternative scenario might arise. As children
living in high-transmission areas grow older, they will acquire
immunity that protects them from clinical episodes more rap-
idly than in children living in low-transmission areas [38], and
they will also acquire antimalarial antibodies more rapidly than
will children living in low-transmission areas [37]. Therefore, in
older children, there will be marked colinearity between anti-
malarial antibody concentrations and clinical immunity, irre-
spective of causality. The subgroup analyses of only the exposed
children removes the confounding resulting from unexposed
children at the time of sampling [26, 27] and, thus, removes the
apparent increase in risk because of residence in an area of high
transmission but cannot address the inevitable colinearity be-
tween antibody concentrations to different malarial antigens
(including causal and noncausal associations with clinical
immunity).
The lower concentrationsof anti-merozoite antibodies inRTS,S-
vaccinated children in our study probably reflected reduced ex-
posure to blood-stage infections, but these antibodies were not
correlates of clinical immunity. Nevertheless, independent of the
anti-merozoite antibodies, when RTS,S vaccinees acquired blood-
stage malaria infections, they were more likely to develop clinical
disease than are unvaccinated individuals. However, the overall
effect of RTS,S in protecting against all forms of malaria infection
meant that RTS,S vaccinees still had a significantly lower incidence
of clinical malaria than did unvaccinated individuals. Protection
was sustained for at least 15 months [39].
Several unexamined caveats prevent us from concluding that
antibodies to the merozoite antigens tested are not capable of
mediating protection. Epitope specificity [40, 41], allele speci-
ficity [42], functional properties [43], isotype [44], avidity [45],
or interactions of responses [46, 47] may be more important
than concentration of antibody. If we plan to continue using
immuno-epidemiological studies to examine these questions, we
will need to consider testing large numbers of antigens and
antibody properties simultaneously [48], adjusting for markers
of exposure [26, 27, 49] and accounting for the extensive co-
linearity between antibody responses [50].
Funding
This work was supported by PATH Malaria Vaccine Initiative,
GlaxoSmithKline Biologicals, theWellcome Trust (to C. D., J. C., and K. M.),
and the NIHR Biomedical Research Centre in Oxford (to P. B.).
Acknowledgments
We thank the participants’ parents; the data and safety monitoring
board, chaired by Malcolm Molyneux; the local safety monitors Jay Berkley
and Firimina Mberesero; Lynn Spencer, Elizabeth Duncan, Ryan Mease,
and Kari Laquer, for technical support; Drs A. Mo and L. Hall, for the kind
provision of EBA-175; and Dr D. Narum, for the kind provision of MSP-3.
Figure 3. Maps of participants' residences, showing the relative AMA-1 antibody concentrations by intensity of shading for the green boxes, relative to
the areas with highest intensity of clinical malaria episodes shown by black circles.
16 d JID 2011:204 (1 July) d Bejon et al
References
1. Guerra CA, Gikandi PW, Tatem AJ, et al. The limits and intensity of
Plasmodium falciparum transmission: implications for malaria control
and elimination worldwide. PLoS Med 2008; 5:e38.
2. Okiro EA, Hay SI, Gikandi PW, et al. The decline in paediatric malaria
admissions on the coast of Kenya. Malar J 2007; 6:151.
3. Global Malaria ProgramSurveillance Monitoring and Evaluation Unit.
Impact of long-lasting insecticidal-treated nets (LLINs) and artemisi-
nin-based combination therapies (ACTs) measured using surveillance
data, in four African countries; Preliminary report based on four
country visits. Geneva, Switzerland: World Health Organization, 2008.
4. Bhattarai A, Ali AS, Kachur SP, et al. Impact of artemisinin-based
combination therapy and insecticide-treated nets on malaria burden in
Zanzibar. PLoS Med 2007; 4:e309.
5. Garcon N, Heppner DG, Cohen J. Development of RTS, S/AS02:
a purified subunit-based malaria vaccine candidate formulated with
a novel adjuvant. Expert Rev Vaccines 2003; 2:231–8.
6. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS, S/AS02A
vaccine against Plasmodium falciparum infection and disease in young
African children: randomised controlled trial. Lancet 2004;
364:1411–20.
7. Bejon P, Lusingu J, Olotu A, et al. Efficacy of RTS, S/AS01E vaccine
against malaria in children 5 to 17 months of age. N Engl J Med 2008;
359:2521–32.
8. Moorthy VS, Ballou WR. Immunological mechanisms underlying
protection mediated by RTS, S: a review of the available data. Malar
J 2009; 8:312.
9. Langhorne J, Ndungu FM, Sponaas AM, Marsh K. Immunity to
malaria: more questions than answers. Nat Immunol 2008; 9:725–32.
10. Bejon P, Andrews L, Andersen RF, et al. Calculation of liver-to-blood
inocula, parasite growth rates, and preerythrocytic vaccine efficacy,
from serial quantitative polymerase chain reaction studies of volun-
teers challenged with malaria sporozoites. J Infect Dis 2005;
191:619–26.
11. Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria
after administration of ultra-low doses of red cells infected with Plas-
modium falciparum. Lancet 2002; 360:610–7.
12. Bejon P, Ogada E, Peshu N, Marsh K. Interactions between age and
ITN use determine the risk of febrile malaria in children. PLoS One
2009; 4:e8321.
13. Beeson JG, Osier FH, Engwerda CR. Recent insights into humoral and
cellular immune responses against malaria. Trends Parasitol 2008;
24:578–84.
14. Fowkes FJ, Richards JS, Simpson JA, Beeson JG. The relationship be-
tween anti-merozoite antibodies and incidence of Plasmodium falci-
parummalaria: a systematic review and meta-analysis. PLoS Med 2010;
7:e1000218.
15. Corran PH, Cook J, Lynch C, et al. Dried blood spots as a source of anti-
malarial antibodies for epidemiological studies. Malar J 2008; 7:195.
16. Angov E, Aufiero BM, Turgeon AM, et al. Development and
pre-clinical analysis of a Plasmodium falciparum Merozoite Surface
Protein-1(42) malaria vaccine. Mol Biochem Parasitol 2003;
128:195–204.
17. Tsai CW, Duggan PF, Jin AJ, et al. Characterization of a protective
Escherichia coli-expressed Plasmodium falciparum merozoite surface
protein 3 indicates a non-linear, multi-domain structure. Mol Biochem
Parasitol 2009; 164:45–56.
18. Zhang D, Pan W. Evaluation of three Pichia pastoris-expressed Plas-
modium falciparum merozoite proteins as a combination vaccine
against infection with blood-stage parasites. Infect Immun 2005;
73:6530–6.
19. Dutta S, Lalitha PV, Ware LA, et al. Purification, characterization, and
immunogenicity of the refolded ectodomain of the Plasmodium falci-
parum apical membrane antigen 1 expressed in Escherichia coli. Infect
Immun 2002; 70:3101–10.
20. Bergmann-Leitner ES, Duncan EH, Mullen GE, et al. Critical evalua-
tion of different methods for measuring the functional activity of an-
tibodies against malaria blood stage antigens. Am J Trop Med Hyg
2006; 75:437–42.
21. Bergmann-Leitner ES, Duncan EH, Burge JR, Spring M, Angov E.
Short report: Miniaturization of a high-throughput pLDH-based
Plasmodium falciparum growth inhibition assay for small volume
samples from preclinical and clinical vaccine trials. Am J Trop Med
Hyg 2008; 78:468–71.
22. Royston P, Altman DG. Regression using fractional polynomials of
continuous covariates: parsimonious parametric modelling. Appl
Statist 1994; 43:429–67.
23. Armitage P, Berry G, Matthews J. Using STATA’s robust cluster
command as appropriate.. Statistical Methods in Medical Research, 4th
ed. Oxford: Blackwell Scientific Publications, 2001.
24. Kulldorff M. SaTScan–Software for the spatial, temporal, and space-
time scan statistics. http://www.satscan.org/. Information Management
Services, 2010.
25. Kulldorff M, Heffernan R, Hartman J, Assuncao R, Mostashari F.
A space-time permutation scan statistic for disease outbreak detection.
PLoS Med 2005; 2:e59.
26. Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to
Plasmodium falciparummerozoite surface protein 2 (MSP2): increasing
prevalence with age and association with clinical immunity to malaria.
Am J Trop Med Hyg 1998; 58:406–13.
27. Bejon P, Warimwe G, Mackintosh CL, et al. Immunity. to febrile
malaria in children: an analysis that distinguishes immunity from lack
of exposure. Infect Immun 2009; 77:1917–23.
28. Lengeler C. Insecticide-treated bednets and curtains for preventing
malaria (Cochrane Review). Cochrane Database Syst Rev 2004,
CD000363.
29. Dent AE, Bergmann-Leitner ES, Wilson DW, et al. Antibody-mediated
growth inhibition of Plasmodium falciparum: relationship to age and
protection from parasitemia in Kenyan children and adults. PLoS One
2008; 3:e3557.
30. McCallum FJ, Persson KE, Mugyenyi CK, et al. Acquisition of growth-
inhibitory antibodies against blood-stage Plasmodium falciparum.
PLoS One 2008; 3:e3571.
31. Sacarlal J, Aide P, Aponte JJ, et al. Long-term safety and efficacy of the
RTS, S/AS02A malaria vaccine in Mozambican children. J Infect Dis
2009; 200:329–36.
32. Guinovart C, Aponte JJ, Sacarlal J, et al. Insights into long-lasting
protection induced by RTS, S/AS02A malaria vaccine: further results
from a phase IIb trial in Mozambican children. PLoS One 2009;
4:e5165.
33. Sama W, Killeen G, Smith T. Estimating the duration of Plasmodium
falciparum infection from trials of indoor residual spraying. Am J Trop
Med Hyg 2004; 70:625–34.
34. Kreuels B, Kobbe R, Adjei S, et al. Spatial variation of malaria incidence
in young children from a geographically homogeneous area with high
endemicity. J Infect Dis 2008; 197:85–93.
35. Belizario VY, Saul A, Bustos MD, et al. Field epidemiological studies on
malaria in a low endemic area in the Philippines. Acta Trop 1997;
63:241–56.
36. Gaudart J, Poudiougou B, Dicko A, et al. Space-time clustering of
childhood malaria at the household level: a dynamic cohort in a Mali
village. BMC Public Health 2006; 6:286.
37. Bousema T, Drakeley C, Gesase S, et al. Identification of hot spots of
malaria transmission for targeted malaria control. J Infect Dis 2010;
201:1764–74.
38. Snow RW, Omumbo JA, Lowe B, et al. Relation between severe malaria
morbidity in children and level of Plasmodium falciparum transmission
in Africa. Lancet 1997; 349:1650–4.
39. Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria
vaccine and exploratory analysis on anti-circumsporozoite antibody
titres and protection in children aged 5-17 months in Kenya and
RTS,S/AS01E and Blood Stage Immunity to Malaria d JID 2011:204 (1 July) d 17
Tanzania: a randomised controlled trial. Lancet Infect Dis 2011;
11:102–9.
40. Corran PH, O’Donnell RA, Todd J, et al. The fine specificity, but not
the invasion inhibitory activity, of 19-kilodalton merozoite surface
protein 1-specific antibodies is associated with resistance to malarial
parasitemia in a cross-sectional survey in The Gambia. Infect Immun
2004; 72:6185–9.
41. Nwuba RI, Sodeinde O, Anumudu CI, et al. The human immune re-
sponse to Plasmodium falciparum includes both antibodies that inhibit
merozoite surface protein 1 secondary processing and blocking anti-
bodies. Infect Immun 2002; 70:5328–31.
42. Takala SL, Coulibaly D, Thera MA, et al. Dynamics of polymorphism in
a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med
2007; 4:e93.
43. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi
T, Druilhe P. Antibodies that protect humans against Plasmodium falci-
parum blood stages do not on their own inhibit parasite growth and
invasion in vitro, but act in cooperation with monocytes. J ExpMed 1990;
172:1633–41.
44. Bouharoun-Tayoun H, Druilhe P. Plasmodium falciparum malaria: ev-
idence for an isotype imbalance which may be responsible for delayed
acquisition of protective immunity. Infect Immun 1992; 60:1473–81.
45. Achtman AH, Stephens R, Cadman ET, Harrison V, Langhorne J.
Malaria-specific antibody responses and parasite persistence after in-
fection of mice with Plasmodium chabaudi chabaudi. Parasite Immunol
2007; 29:435–44.
46. Osier FH, Fegan G, Polley SD, et al. Breadth andmagnitude of antibody
responses to multiple Plasmodium falciparum merozoite antigens are
associated with protection from clinical malaria. Infect Immun. 2008;
76:2240–8.
47. Nebie I, Diarra A, Ouedraogo A, et al. Humoral responses to Plasmo-
dium falciparum blood-stage antigens and association with incidence of
clinical malaria in children living in an area of seasonal malaria trans-
mission in Burkina Faso, West Africa. Infect Immun 2008; 76:759–66.
48. Crompton PD, Kayala MA, Traore B, et al. A prospective analysis of the
Ab response to Plasmodium falciparum before and after a malaria
season by protein microarray. Proc Natl Acad Sci U S A 2010;
107:6958–63.
49. Drakeley CJ, Corran PH, Coleman PG, et al. Estimating medium- and
long-term trends in malaria transmission by using serological markers
of malaria exposure. Proc Natl Acad Sci U S A 2005; 102:5108–13.
50. Gray JC, Corran PH, Mangia E, et al. Profiling the antibody immune
response against blood stage malaria vaccine candidates. Clin Chem
2007; 53:1244–53.
18 d JID 2011:204 (1 July) d Bejon et al
